Healthshots on MSN10d
RSV or Respiratory Syncytial Virus: Is it a serious infection or just common cold?
Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...
Glamour on MSN5d
The RSV Vaccine for Infants: Everything Parents Need to Know
The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...
Glamour on MSN15d
RSV Symptoms: Here’s How the Virus Shows Up Differently in Babies, Adults, and Seniors
Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...
Medpage Today on MSN5d
Real-World Data on the RSV Vaccine for Older Adults
Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
Too Old to Operate10d
Long-Term Health Decline Linked to Lower Respiratory Tract Infections
The following is a summary of “Sex differences in the impact of lower respiratory tract infections on older adults’ health ...
MedPage Today9d
Year in Review: RSV
Opens in a new tab or window In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and older to protect against lower respiratory tract disease. Approval was ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Business Wire24d
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
Indication for AREXVY AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals ...